US2002090711A1PendingUtilityA1

Process for preparing latent antithrombin III

42
Priority: Nov 20, 2000Filed: Nov 8, 2001Published: Jul 11, 2002
Est. expiryNov 20, 2020(expired)· nominal 20-yr term from priority
Inventors:Göran Karlsson
A61K 38/00C12P 21/02C07K 14/8128
42
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A process for the preparation of latent antithrombin III is provided. The process comprises incubation of a solution of native antithrombin III in the presence of sulfate ions and a buffer selected from the Good's zwitterionic buffers.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A process for the preparation of latent antithrombin III, comprising incubating a solution of native antithrombin III in the presence of sulfate ions and a buffer selected from the Good's zwitterionic buffers.  
     
     
         2 . A process according to  claim 1 , wherein said sulfate ions are provided as a salt selected from the group consisting of ammonium sulfate, alkali metal sulfates and alkaline earth sulfates.  
     
     
         3 . A process according to  claim 2 , wherein said sulfate salt is ammonium sulfate.  
     
     
         4 . A process according to  claim 1 , wherein the concentration of said sulfate ions is from 0.5 to 2.0 M.  
     
     
         5 . A process according to  claim 4 , wherein the sulfate ion concentration is from 0.7 to 1 M.  
     
     
         6 . A process according to  claim 5 , wherein the sulfate ion concentration is from 0.8 to 0.9 M.  
     
     
         7 . A process according to  claim 1 , wherein said buffer comprises a HEPES buffer.  
     
     
         8 . A process according to  claim 1 , wherein the concentration of said buffer is from 1 to 25 mM.  
     
     
         9 . A process according to  claim 8 , wherein the buffer concentration is from 2.5 to 10 mM.  
     
     
         10 . A process according to  claim 9 , wherein the buffer concentration is from 4 to 6 mM.  
     
     
         11 . A process according to  claim 1 , wherein the pH value is from 6 to 9.  
     
     
         12 . A process according to  claim 11 , wherein the pH value is from 7 to 8.  
     
     
         13 . A process according to  claim 12 , wherein the pH value is from 7.4 to 7.6.  
     
     
         14 . A process according to  claim 1 , further comprising treating said latent antithrombin III to inactivate or remove pathogens in or from said latent antithrombin III.  
     
     
         15 . The process of  claim 14 , wherein said pathogen is a virus or a prion.  
     
     
         16 . A process according to  claim 14 , wherein said treatment comprises at least one method selected from the group consisting of chemical inactivation, heat inactivation, light inactivation, microwave inactivation and nano-filtration removal.  
     
     
         17 . A process according to  claim 1 , further comprising isolating said latent antithrombin from said solution.  
     
     
         18 . A process according to  claim 17 , wherein said isolating step comprises affinity chromatography or hydrophobic interaction chromatography.  
     
     
         19 . A process according to  claim 1 , wherein said buffer comprises a MES buffer.  
     
     
         20 . A process according to  claim 1 , wherein said buffer comprises a PIPES buffer.

Join the waitlist — get patent alerts

Track US2002090711A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.